Prolonged cold ischemia storage (CIS) is a leading risk factor for poor transplant outcome. Existing strategies strive to minimize ischemia-reperfusion injury in transplanted organs, yet there is a need for novel approaches to improve outcomes of marginal allografts and expand the pool of donor organs suitable for transplantation.
| INTRODUCTION
Ischemia-reperfusion injury (IRI) is an unavoidable consequence of solid organ transplantation. The negative impact of IRI on cells and tissues arises from the complex network of events, including oxygen and nutrient deprivation, disruption of cellular homeostasis, reactive oxygen species generation, and inflammation. 1 In addition, IRI directly or indirectly enhances anti-donor cellular and humoral responses.
Prolonged cold ischemia storage (CIS) is an independent risk factor for poor transplant outcome. CIS is associated with early graft loss and increased incidence of acute and chronic rejection. [2] [3] [4] [5] Patients receiving transplants subjected to long-term CIS are commonly treated with more aggressive immunosuppression. Furthermore, some solid organ allografts subjected to prolonged CIS are considered high risk and are not transplanted, exacerbating the problem of organ shortage. Current therapeutic options specifically controlling IRI are limited to organ pretreatment and modified perfusion and preservation conditions.
Aquaporins (AQPs) are water channels that facilitate passive water transfer across the cell membrane in response to osmotic gradients.
In mammals, there are 13 AQP family members (AQP0-AQP12), with AQPs 3, 7, and 9 transporting glycerol and other small molecules in addition to water (aquaglyceroporins). [6] [7] [8] AQPs are expressed in all
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tissues and organs and are involved in many physiological processes, including urine concentration, brain water homeostasis, angiogenesis, neural excitability, and cell migration. 8 Recent studies demonstrate roles of several aquaglyceroporins in innate and adaptive immunity.
AQPs 3 and 7 are expressed by immature dendritic cells and facilitate antigen uptake through micropinocytosis. 9 AQP3 is expressed in T cells and macrophages and is required for chemokine-dependent cell migration. 10, 11 Aquaglycerol channel AQP9 is upregulated in activated CD8 T cells and is critical for the development of T cell memory.
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AQP4 expression was initially described in renal collective ducts, renal epithelial cells, and brain astrocytes. 13 AQP4 is also expressed by cardiomyocytes, and AQP4 deficiency results in reduced myocardial tissue damage and edema during infarction. 14, 15 These findings suggest that blocking AQP4 may attenuate IRI as well as innate and adaptive immune responses after transplantation. However, the possibility of blocking water channels with the purpose of improving transplant survival has not been previously explored, largely due to the lack of reagents selectively targeting specific AQPs.
The goal of the present study was to investigate whether inhibition of AQP4 alone or in combination with other therapies can be used to prolong survival of high-risk mouse cardiac allografts. We used a small molecule inhibitor that specifically blocks AQP4, with limited inhibition of AQP1 and AQP5. To approximate a clinical situation in a mouse transplant model, donor heart allografts were subjected to 8 hours of CIS. Contrary to our initial hypothesis, blocking AQP4 during donor heart collection and storage and for a short-time posttransplantation did not affect the early expression of inflammatory markers characteristic of IRI. Nevertheless, AQP4 inhibition improved the viability of donor graft cells after 8 hours of CIS, diminished anti-donor T cell responses, and prolonged allograft survival in the absence of other immunosuppression. Furthermore, AQP4 inhibition enhanced the efficacy of cytotoxic T lymphocyte-associated antigen 4 (CTLA4)-Ig costimulatory blockade in prolonging the survival of heart allografts subjected to 8 hours of CIS. Our results suggest that the graft-prolonging effects of AQP4 blockade are at least in part mediated through the direct inhibition of donor-reactive T cell expansion and cytokine production. Jackson Laboratories (Bar Harbor, ME). All animals were maintained and bred in the pathogen-free facility at the Cleveland Clinic. All procedures involving animals were approved by the Institutional Animal
| METHODS

| Animals
Care and Use Committee at the Cleveland Clinic.
| Heart transplantation
Vascularized heterotopic cardiac transplantations were performed as previously described. 16, 17 BALB/c heart allografts were preserved 
| AQP inhibitors
A small molecule inhibitor of AQP4, AER-270, was identified by high-throughput screening. Briefly, Chinese hamster ovary (CHO) cell-lines expressing N-terminal FLAG-tagged human AQP1, AQP4a, AQP4b, AQP5, mouse AQP4-M23, or unrelated protein CHO-CD81
were generated by using the Flp-In TM system (Life Technologies, Carlsbad, CA) and subjected to hypo-osmotic shock and water per- 
| Flow cytometry
Fluorochrome-conjugated mAbs and PE-conjugated Annexin V were Cambridge, UK) were used. Spleen or graft-infiltrating cells were isolated and stained as previously described. [18] [19] [20] At least 200,000 events per sample were acquired on a BD Bioscience LSRII followed by data analysis using FlowJo software (Tree Star Inc., Ashland, OR).
| ELISPOT assays
Interferon (IFN)γ ELISPOT assays were performed as previously described using capture and detecting anti-mouse cytokine antibody from BD Biosciences. [20] [21] [22] Recipient spleen cells were stimulated with mitomycin C-treated donor BALB/c or third-party SJL spleen cells for 24 hours. The resulting spots were analyzed by using an ImmunoSpot Series 4 analyzer (Cellular Technology, Cleveland, OH).
| RNA isolation and quantitative real-time PCR analysis
Portions of heart allografts were frozen in liquid nitrogen and stored at −80°C. Spleen CD4 + and CD8 + cells were purified using negative selection mouse T cell isolation kit from STEMCELL technologies (Vancouver, Canada) followed by staining for CD4, CD8, and CD44 markers and flow sorting (FACSAria; BD Biosciences). Total RNA was RNA amplification and calculated relative to the expression of the target gene in heart tissue from naive B6 mice.
| T cell proliferation assay
Flat-bottom 96-well plates were precoated with anti-mouse CD3
(clone 2C11, 2 μg/mL; eBioscience) and anti-mouse CD28 (clone 37.51, 4 μg/mL; eBioscience) overnight at 4°C. T cells isolated from spleens of naive B6 mice using the negative selection mouse T cell isolation kit from STEMCELL technologies were labeled with CFSE as previously published, 23 and 0.1 × 10 6 aliquots were cultured on anti-CD3/anti-CD28 precoated plates at 37°C. AER-270 at 0.125-10 μM or DMSO diluent (equivalent to DMSO content in 10 μM AER-270 dilution) was added to the wells. Cells were harvested after 72 hours, and CFSE dilution was assessed by flow cytometry.
| Statistical analysis
Heart allograft survival was compared between groups by KaplanMeier analysis. Differences between groups during recall immune responses were analyzed by using a nonparametric equivalent of 1-way ANOVA, the Kruskal-Wallis test. When the overall P value was <.05, pairwise comparisons were carried out by using the MannWhitney test. A value of P < .05 was considered statistically significant.
| RESULTS
| AQP4 inhibition during CIS reduces cell apoptosis in explanted donor heart
A small molecule inhibitor of AQP4, AER-270, was identified by high-throughput screening. AER-270 inhibited AQP4a and AQP4b
(60.5 ± 1.4% and 55.2 ± 1.6% inhibition, respectively) and mouse 
| AER-270/271 treatment inhibits early CD8 T cell infiltration into heart allografts
Based on the demonstrated role of AQP4 during brain and heart ischemia, 14, 26 we hypothesized that AQP4 blockade ameliorates the consequences of IRI and, thus, extends transplant survival.
Unexpectedly, AQP4 inhibition did not alter the intragraft expres- T cells compared with control heart allografts subjected to 8 hours of CIS ( Figure 3C ). These data suggest that the AQP4 blockade inhibits early infiltration of endogenous memory CD8 T cells into heart allografts, an event that precedes priming of donor-reactive T cells in the spleen. 27 As anticipated, the numbers of graft-infiltrating T cells increased by day 5 after transplantation. At that point, both CD4 and CD8 T cell infiltration was reduced by AER-270/271 treatment ( Figure 3D ).
| AQP4 blockade by AER-270/271 directly inhibits T cell proliferation and effector functions
Flow cytometry analysis of naive B6 splenocytes revealed AQP4 expression on both CD4 and CD8 T cells but not on B cells ( Figure 4A ).
In both CD4 and CD8 subsets, CD44 hi effector/memory T cells expressed higher levels of AQP4 compared with CD44 lo naive T cells. 
| AQP4 inhibition is synergistic with CTLA4-Ig to prolong the survival of heart allografts subjected to 8 hours of CIS
We previously reported that subjecting mouse heart allografts to 8 hours of CIS interfered with graft-prolonging effects of costimulatory blockade, mainly due to reactivation of endogenous memory CD8
T cells. 17 We, therefore, tested whether a short peritransplantation treatment with AQP4 inhibitor improves the efficacy of CTLA4-Ig in these settings. Consistent with our previous findings, the major- 
| DISCUSSION
Our study was prompted by recent findings that AQP4 is expressed on cardiac myocytes and is protective during ischemic cardiac tissue injury. 14 Treatment of donor hearts with the AQP4 inhibitor during collection, perfusion, and storage significantly reduced the rate of cellular F I G U R E 3 AER-270/271 treatment inhibits early CD8 T cell infiltration into heart allografts. Heart allograft procedure and treatments were performed as in Figure 2B , Our study provides the first demonstration that AQP4 is expressed on CD4 and CD8 T lymphocytes and that inhibition of AQP4 modulates T cell activation and function. These findings identify a new direction for future studies in transplant therapy. The potency of short-term AQP4 inhibition in a robust model of heart allograft rejection makes it a promising strategy for improving survival of marginal organ transplants in combination with other forms of immunosuppression.
